Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.For the
Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.
For the period, ADAC reported revenues of $68.4 million, a 24%increase over the $55 million in sales reported for the firstquarter of 1996. Net income grew 44% to $5.1 million, comparedwith $3.5 million in the same period of 1996. ADAC also reportedrecord bookings of $82 million, adding $13 million to its backlog.
ADAC said the revenue growth was due to a 10% increase in servicerevenue and a 30% increase in product revenue. Product gross marginsgrew 3.7% to 41.8% in the period. ADAC also began volume shipmentsof its Molecular Coincidence Detection (MCD) high-energy imagingtechnique in the quarter.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.